

1 **Prevalence of polymyxin resistant bacterial strains in India: a systematic**  
2 **review and meta-analysis**

3

4

5 Running title- Polymyxin-resistant bacterial strains in India

6

7

8 **Sambit K. DWIBEDY<sup>1,2</sup>, Indira PADHY<sup>1</sup>, Aditya K. PANDA<sup>1,3</sup>, Saswat S.**  
9 **MOHAPATRA<sup>1,3\*</sup>**

10

11 <sup>1</sup>Department of Biotechnology, Berhampur University, Bhanja Bihar, Berhampur- 760007,  
12 Odisha, India

13 <sup>2</sup>Department of Zoology, SBRG Women's College, Berhampur- 760001, Odisha, India

14 <sup>3</sup>Centre of Excellence on Bioprospecting of Ethno-pharmaceuticals of Southern Odisha  
15 (CoE-BESO), Berhampur University, Bhanja Bihar, Berhampur- 760007, India

16

17

18 For Correspondence-

19 Saswat S. Mohapatra, Ph.D.

20 Assistant Professor, Department of Biotechnology, Berhampur University, Bhanja Bihar,  
21 Berhampur- 760007. Email: [saswatsmohapatra@gmail.com](mailto:saswatsmohapatra@gmail.com)

22 **Abstract**

23 **Introduction:** Polymyxins, the cationic lipopeptide antibiotics, are the last line of  
24 therapeutics against the MDR Gram-negative bacterial (GNB) pathogens. Unfortunately, the  
25 rising cases of polymyxin-resistant strains from across the globe have adversely impacted  
26 their utility. While the molecular mechanisms responsible for developing polymyxin  
27 resistance (Pol<sup>R</sup>) are largely understood, the prevalence of Pol<sup>R</sup> strains in India has not been  
28 investigated systematically. The current study was undertaken to primarily determine the  
29 prevalence of Pol<sup>R</sup> strains in India. Moreover, the extent of the spread of mobile colistin  
30 resistance (*mcr*) genes among the GNB strains in India was also determined.

31 **Method:** A systematic search for articles using the relevant inclusion and exclusion criteria  
32 was performed in the applicable databases for the period January 2015 to December 2023.  
33 The included 41 studies were subjected to a meta-analysis using the Comprehensive Meta-  
34 Analysis software (V.4). Publication biases were assessed using funnel plots and Egger's  
35 regression analysis.

36 **Result:** Considering a total of 41 studies including 24,589 bacterial isolates the present meta-  
37 analysis found the rate of Pol<sup>R</sup> bacteria in India to be at 15.0% (95% CI: 11.2 to 19.8).  
38 Among the Indian States, Tamil Nadu topped with the highest prevalence of Pol<sup>R</sup> at 28.3%.  
39 Investigating the contribution of the *mcr* genes, it was observed that among the Pol<sup>R</sup> strains,  
40 8.4% (95% CI: 4.8 to 14.3) were *mcr* positive.

41 **Conclusion:** The study determined the prevalence of Pol<sup>R</sup> strains in India at 15.0% which is  
42 higher than that of the global average at 10%. The study also determined that 8.4% of the  
43 Pol<sup>R</sup> strains carried the *mcr* genes. The *mcr*-positive strains reported from India could be an  
44 underestimation of the actual numbers due to the non-inclusion of *mcr* screening in many  
45 previous studies. This study provides insight into the state of the Pol<sup>R</sup> situation in India,  
46 which may be useful to develop a monitoring strategy to contain the spread of such strains  
47 and preserve the efficacy of the polymyxins.

## 48 INTRODUCTION

49 The significant use of antibiotics in healthcare, and agriculture, and their indiscriminate  
50 prophylactic consumption has driven the rise of antibiotic-resistant bacterial pathogens.  
51 Infections caused by antibiotic-resistant bacteria are increasingly becoming fatal due to the  
52 non-availability of effective antibiotics against them. As per an estimate, drug-resistant  
53 pathogens caused 4.95 million deaths in 2019,<sup>1</sup> which is predicted to rise to 10 million deaths  
54 per annum by 2050.<sup>2</sup> Considering the significant economic consequences of rising drug-  
55 resistant infections, urgent mitigation measures are warranted.

56 Antibiotic-resistant bacteria belonging to the Gram-negative type pose a formidable challenge  
57 to treatment as increasing reports of resistance to third and fourth generations of  
58 cephalosporins are reported globally.<sup>3</sup> In this unprecedented scenario, polymyxins, a group of  
59 cationic lipopeptide antibiotics, remain the last option for treatment.<sup>4,5</sup> Polymyxin was  
60 initially isolated in 1947 from a soil bacterium *Paenibacillus polymyxa*<sup>6</sup> and approved for  
61 clinical use in 1959 against Gram-negative bacteria (GNB). Due to their nephrotoxic and  
62 neurotoxic properties, polymyxins were prohibited for clinical use in the 1970 s<sup>7,8</sup> and were  
63 consequently substituted by aminoglycosides, quinolones, and  $\beta$ -lactams. However, with the  
64 rising infections caused by MDR GNB such as *Klebsiella pneumoniae*, *Acinetobacter*  
65 *baumannii*, and *Pseudomonas aeruginosa*, and failure of the frontline antibiotics, polymyxins  
66 have re-emerged albeit with some modifications in the chemical structure as the last-resort  
67 antibiotics against them.<sup>4,9</sup>

68 Polymyxins are of five types (polymyxin A to polymyxin E), of which polymyxin B and  
69 polymyxin E (colistin) are approved for clinical use.<sup>10</sup> Structurally, polymyxins are cationic  
70 decapeptides consisting of a central cyclic heptapeptide with a tripeptide side-chain acylated  
71 at the N-terminus by a fatty acid tail.<sup>11,12</sup> Polymyxins primarily target the negatively charged  
72 outer membrane (OM) of GNB, where they disrupt the lipopolysaccharide (LPS) structure  
73 causing membrane damage and cell death.<sup>5,13,14</sup>

74 The extensive use of polymyxins in the preceding decade in both healthcare and animal feeds  
75 has triggered the emergence of polymyxin-resistant (Pol<sup>R</sup>) bacterial strains. Pol<sup>R</sup> bacterial  
76 species such as *K. pneumoniae*,<sup>15-17</sup> *P. aeruginosa*,<sup>4,18</sup> *A. baumannii*,<sup>19</sup> *E. coli*,<sup>20</sup> *Shigella*  
77 *sonnei*,<sup>21</sup> *Salmonella enterica*,<sup>22</sup> *Enterobacter aerogenes* and *Enterobacter cloacae*<sup>23</sup> have  
78 been reported from across the globe adversely affecting the healthcare sector. Moreover, the

79 detection of Pol<sup>R</sup> GNB in both clinical and environmental samples has made the situation  
80 concerning.

81 The primary mechanism responsible for Pol<sup>R</sup> development is the OM remodelling or  
82 modification in GNB making it increasingly positive [by the addition of 4-amino-4-deoxy L-  
83 arabinose (L-Ara4N) or phosphoethanolamine (pEtN)], leading to the repulsion of cationic  
84 polymyxins.<sup>4,13,24</sup> The OM remodelling is generally carried out by bacterial two-component  
85 signal transduction systems (TCS), of which PhoPQ and PmrAB are the prominent ones.<sup>13,24</sup>  
86 Moreover, bacterial species such as *Serratia marcescens*, *Proteus mirabilis*, *Providencia*  
87 *rettgeri*, *Vibrio cholerae*, *Campylobacter spp.*, *Legionella spp.*, *Morganella morganii*,  
88 *Burkholderia spp.*, *Edwardsiella spp.*, *Aeromonas hydrophila*, *Acinetobacter junii*, *Neisseria*  
89 *spp.* etc. are intrinsically resistant to polymyxins due to the permanent modification of their  
90 OM.<sup>4,24,25</sup>

91 Chromosome-encoded polymyxin resistance though is the prevalent mechanism, bacteria can  
92 acquire polymyxin resistance via the plasmid-borne mobile colistin resistance (*mcr*) gene. In  
93 this context, the first detection of *mcr* plasmids in 2015 from *E. coli* and *K. pneumoniae*  
94 strains in China is significant.<sup>20</sup> The *mcr* gene encodes a pEtN transferase enzyme that  
95 catalyses the addition of a pEtN residue to lipid-A moiety which alters the net charge of the  
96 LPS. To date, ten different classes of *mcr* genes (*mcr-1* to *mcr-10*) including several variants  
97 have been discovered among many GNB pathogens.<sup>26,27</sup> Plasmids carrying *mcr* genes have  
98 been reported from across the globe showing distinct geographical distribution.<sup>26,28</sup> As the  
99 potential of rapid dissemination of plasmid-borne *mcr* genes is significantly high, it is  
100 pertinent to conduct periodic surveillance to monitor their distribution in the environment and  
101 clinic.

102 In India, *mcr* genes have been reported in several studies conducted using clinical samples,<sup>29</sup>  
103 hospital sewage,<sup>30</sup> urban sewage water,<sup>31</sup> and food samples.<sup>32</sup> However, a comprehensive  
104 analysis of the distribution of *mcr* genes across India is lacking. It is important to highlight  
105 that the increasing number of carbapenem-resistant pathogenic bacteria has made India one of  
106 the top users of polymyxins in the hospital setting. Furthermore, the use of colistin as a  
107 growth promoter in poultry farms has triggered the spread of Pol<sup>R</sup> GNB in the environment.  
108 Though the Govt. of India has banned the use of colistin in farm animals since 2019, the  
109 impact of their extensive use before 2019 is yet to be assessed.

110 Studies reporting the prevalence of Pol<sup>R</sup> strains in India are very limited and the reports of  
111 *mcr*-positive bacterial strains are also rare. The current study employing a systematic review  
112 and meta-analysis was undertaken to gain an insight into the prevalence of Pol<sup>R</sup> bacterial  
113 strains across India from both clinical and environmental sources. Moreover, the study also  
114 attempted to estimate the *mcr*-positive bacterial strains in India with a particular emphasis on  
115 their geographical distribution in the Indian sub-continent.

## 116 **MATERIALS & METHODS**

117 Using published articles, the present systematic review and meta-analysis was conducted to  
118 determine the prevalence and spread of Pol<sup>R</sup> GNB from clinical and environmental sources in  
119 India and the contribution of *mcr* genes in gaining the Pol<sup>R</sup> phenotype. The study was  
120 undertaken as per the guidelines of Systematic Reviews and Meta-Analyses (PRISMA)<sup>33</sup>  
121 (Fig. 1) (Supplementary Table 3).

### 122 **Data collection**

123 The databases such as PubMed, Google Scholar, Science Direct, and Scopus were  
124 extensively searched using the keywords “polymyxin resistance”, “colistin resistance”,  
125 “mobile colistin resistance gene” and “India”. Original studies reporting the presence of Pol<sup>R</sup>  
126 bacterial strains as well as *mcr*-positive strains in India, published between January 2015 to  
127 December 2023 were included in this study. As the first report of *mcr*-positive bacterial  
128 strains came in 2015,<sup>20</sup> we selected the timeline from 2015 to 2023 for the meta-analysis to  
129 determine the prevalence of both Pol<sup>R</sup> and *mcr*-positive bacterial strains in India.

### 130 **Inclusion criteria**

131 As the primary objective of the study was to determine the prevalence of Pol<sup>R</sup> bacterial  
132 strains in India, all studies reporting such strains irrespective of their origin were considered.  
133 Studies involving surveillance of hospital samples, sewage samples, food materials, etc. were  
134 analysed. A bacterial isolate was considered Pol<sup>R</sup> if the MIC to colistin was > 2 mg/L  
135 determined using the broth microdilution (BMD) method<sup>34,35</sup>, whereas a strain was  
136 considered *mcr*-positive if a particular *mcr* class or any of its variants was amplified by PCR.  
137 For the meta-analysis, the following inclusion criteria were followed: 1) the samples used in  
138 the studies must hail from India irrespective of their source of isolation, 2) data on resistance  
139 to polymyxin B and/or colistin must be available, 3) BMD method must have been used to  
140 determine Pol<sup>R</sup> of the bacterial isolates, 4) the article must mention the total sample size and  
141 the number of Pol<sup>R</sup> strains isolated or the prevalence frequency, 5) the sample size should not

142 be smaller than five for Pol<sup>R</sup> and one for *mcr* gene positive, and 6) the article must have been  
143 published in English.

#### 144 **Exclusion criteria**

145 The following exclusion criteria were strictly followed during the analysis: 1) studies with no  
146 Pol<sup>R</sup> isolate were excluded; 2) studies conducted outside India were not considered; 3) studies  
147 that employed resistance detection methods other than BMD were excluded; 4) studies that  
148 were not published in English, were not peer-reviewed, and were published before 2015 were  
149 excluded.

#### 150 **Data extraction**

151 Data were extracted from relevant articles that were qualified based on the study's inclusion  
152 and exclusion criteria (Fig. 1). Each report was individually screened and investigated for  
153 eligibility by two different authors (SKD and IP). Following a thorough review, the following  
154 information was extracted and summarised for each study: first author name, publication  
155 year, State, or UT (Union Territories) of occurrence, total sample size, the total number of  
156 Pol<sup>R</sup> isolates, reported Pol<sup>R</sup> bacteria, resistance detection method, genes involved in  
157 resistance development, and *mcr* gene screening status. For further analysis, the data were  
158 tabulated in a Microsoft Excel sheet.

#### 159 **Subgrouping of data**

160 The research articles with Pol<sup>R</sup> reports were classified into two groups based on criteria such  
161 as sample size (more than five) and the involvement of *mcr* genes in the development of Pol<sup>R</sup>.  
162 Studies reporting a specific number of samples containing both Pol<sup>R</sup> and susceptible isolates  
163 and a particular number of Pol<sup>R</sup> bacteria as events were placed in the first group. This group  
164 was further subdivided based on two criteria: geographical location (the States or UTs from  
165 where they were reported) and the source of their isolation (clinical or environmental). In this  
166 classification system, those States were included that have at least four different reports on  
167 Pol<sup>R</sup> isolates. In the second group, those reports were included where *mcr* gene screening  
168 status was mentioned clearly in the study.

#### 169 **Quality assessment**

170 The quality of all eligible reports was determined by the Newcastle–Ottawa Scale (NOS) and  
171 only the high-quality reports were considered for the present meta-analysis. According to the

172 NOS guidelines, qualitative scores are given as stars, and a total score of five stars or more  
173 for a study is considered a high-quality report.

#### 174 **Meta-analysis**

175 The meta-analysis was performed using the relevant studies and reports to determine the  
176 prevalence of Pol<sup>R</sup> bacteria in India, and the contribution of *mcr* genes in Pol<sup>R</sup> phenotype. All  
177 statistical analyses were performed using the Comprehensive Meta-Analysis (CMA) software  
178 (version 4.0; Biostat Inc. USA). The generated data were visualized using forest plots.  
179 Publication bias in the included studies was assessed using funnel plots with visual analysis<sup>36</sup>  
180 and Egger regression analysis.<sup>37</sup> The heterogeneity of the studies was examined using the  
181 Cochran Q statistics<sup>38</sup> and I<sup>2</sup> statistics.<sup>39</sup> Based on the outcome of the heterogeneity analysis,  
182 a fixed-effect model (homogenous) or random-effect model (heterogeneous) was used for the  
183 meta-analysis.

184 The combined event rate and 95% confidence interval were calculated to determine the  
185 frequency of Pol<sup>R</sup> isolates in India and the contribution of *mcr* to polymyxin resistance. In  
186 addition, sensitivity analysis was performed to explore the robustness of the meta-analysis by  
187 excluding one study at a time, performing the meta-analysis, and comparing it with the results  
188 of the parent analysis.

### 189 **RESULTS**

#### 190 **Literature review and screened results**

191 Overall, 1408 articles were obtained by searching different databases with suitable keywords  
192 (PubMed = 802, Google Scholar = 431, Science Direct = 109, Scopus = 66). The article  
193 selection approach is presented in the PRISMA flow chart (Fig. 1). A total of 41 eligible  
194 articles reporting Pol<sup>R</sup> (Supplementary Table 1) were included in the meta-analysis. For  
195 determining the contribution of *mcr* genes in Pol<sup>R</sup>, 58 studies were considered of which 40  
196 studies were found to be eligible for the meta-analysis (Supplementary Table 2) based on the  
197 stipulated inclusion and exclusion criteria.

#### 198 **Publication bias**

199 Visual analysis of the funnel plot and Egger's regression analysis showed the absence of  
200 publication bias in the analysis of the incidence of Pol<sup>R</sup> bacteria in India (intercept: 0.37, 95%  
201 CI: -2.73 to 3.46, p = 0.81), as well as in the analysis of the role of the *mcr* gene in Pol<sup>R</sup>  
202 (intercept: -1.3, 95% CI: -2.69 to 0.08, p = 0.065) (Table 1) (Supplementary Fig. 1).



203 Furthermore, after the categorization of all studies according to the geographical locations  
204 (States) from which they were reported, the funnel plot and Egger's regression analysis  
205 revealed no significant biases while analysing the incidence of Pol<sup>R</sup> bacteria in states such as  
206 Delhi, Odisha, Tamil Nadu, and Uttar Pradesh (Table 1) (Supplementary Fig. 2).

### 207 **Heterogeneity analysis**

208 Cochran Q and I<sup>2</sup> measurements demonstrated significant heterogeneity among the included  
209 studies. Hence, a random-effects model was used for all meta-analyses (Table 1).

### 210 **Prevalence of Pol<sup>R</sup> bacteria in India**

211 After analysing 41 reports, accounting for 24,589 bacterial isolates tested, the present meta-  
212 analysis found that the rate of Pol<sup>R</sup> bacteria in India was 15.0% (95% CI: 11.2 to 19.8) (Fig.  
213 2A). Out of the 28 states and eight UTs in India, 12 states and 3 UTs have reported the  
214 presence of Pol<sup>R</sup> bacterial strains. Interestingly, 16 states and 5 UTs in India have not  
215 reported the presence of Pol<sup>R</sup> strains. The overall spread of the Pol<sup>R</sup> GNB strains in the Indian  
216 subcontinent is shown in Fig. 2B. Among all the states that have reported Pol<sup>R</sup>, Tamil Nadu,  
217 Uttar Pradesh, and Odisha are the top three with the rate of Pol<sup>R</sup> at 28.3%, 16.3%, and 15.9%,  
218 respectively, which is higher than the overall prevalence of Pol<sup>R</sup> in the Indian subcontinent  
219 (Fig. 3). Moreover, among the other states in India Pol<sup>R</sup> prevalence in Delhi was found to be  
220 quite high at 13.7%, though less than the national average (Fig. 3).

221 A breakdown of the Pol<sup>R</sup> GNB strains by the source of their isolation revealed that 89%  
222 (1875 isolates) of them were from clinical sources, whereas the remaining 11% (227 isolates)  
223 were from the environmental samples (Fig. 4A). Bacterial strains isolated in hospitals from  
224 various samples such as stool, pus, urine, wound etc. were considered as clinical isolates  
225 though further sub-categorization was not performed in the current study. However, among  
226 the environmental sources, water (46%), vegetables (45%), poultry products (8%), and dairy  
227 farms (1%) were the major contributors for Pol<sup>R</sup> strains (Fig. 4A). Employing meta-analysis  
228 on 36 eligible clinical reports, the rate of Pol<sup>R</sup> was found to be 13.5% (95% CI: 10.0 to 17.9)  
229 (Fig. 4B), whereas a similar analysis using 5 environmental reports the Pol<sup>R</sup> rate was found to  
230 be 27.6% (95% CI: 11.0 to 54.2) (Fig. 4C).

### 231 **Role of *mcr* gene in the development of Pol<sup>R</sup>**

232 To understand the prevalence of *mcr* genes in Pol<sup>R</sup> bacterial isolates in India in comparison  
233 with other possible mechanisms, 40 eligible reports with positive *mcr* gene screening status



234 and a sample size of more than one (Pol<sup>R</sup> isolate) criterion were considered for the analysis  
235 (Supplementary Table 2). Out of the 1606 bacterial isolates tested for the presence of *mcr*  
236 genes by PCR, 76 strains were found to be positive. The meta-analysis result showed that the  
237 contribution of the *mcr* gene to the rise in polymyxin resistance was 8.4% (95% CI: 4.8-14.3)  
238 in India (Fig. 5A).

239 Analysing the State wise detection of the *mcr* genes, nine states were found to have reported  
240 the presence of *mcr* genes (Fig. 5B), among which Uttar Pradesh has the highest number of  
241 reports at 48 followed by Tamil Nadu and Assam with 31 and 15 reports respectively.  
242 Analysing the prevalence of particular classes of *mcr* genes, it was revealed that in India, so  
243 far six classes of *mcr* genes namely *mcr-1*, *mcr-2*, *mcr-3*, *mcr-4*, *mcr-5*, and *mcr-9* have been  
244 detected (Table 2). Among the *mcr* classes, the present analysis identified the *mcr-1* to be the  
245 predominant one and found in 72% of the isolates, whereas the frequencies of *mcr-2*, *mcr-3*,  
246 *mcr-4*, *mcr-5*, and *mcr-9* were 3%, 19%, 3%, 1%, and 2%, respectively (Fig. 5C).

#### 247 **Sensitivity analysis**

248 Sensitivity analysis was performed to measure the robustness of the meta-analysis by  
249 excluding a single study each time and relating the results to the parental meta-analysis. As  
250 illustrated in Supplementary Fig. 3, no significant deviation was observed in the sensitivity  
251 analysis compared with the original meta-analysis results for studying the incidence of Pol<sup>R</sup>  
252 bacteria in India. Furthermore, the meta-analysis on the contribution of the *mcr* genes to Pol<sup>R</sup>  
253 also revealed a robust observation, as shown in Supplementary Fig. 4.

#### 254 **DISCUSSION**

255 The current meta-analysis systematically evaluated the prevalence of Pol<sup>R</sup> bacteria in India,  
256 which was higher than the global average. In this study, we found that 15.0% of GNB were  
257 Pol<sup>R</sup> (Fig. 2), whereas the global average remained at 10%.<sup>40</sup> A previous study has put the  
258 rate of Pol<sup>R</sup> among clinical Enterobacteriaceae isolates in India at 13.8%.<sup>41</sup>

259 The present study revealed that GNB resistant to polymyxins is spread all over India, and  
260 States like Tamil Nadu, Uttar Pradesh, and Odisha have a higher prevalence of Pol<sup>R</sup> strains  
261 than the national average (Fig. 2B, Fig. 3). The rising incidence of Pol<sup>R</sup> in India could be  
262 attributed to their indiscriminate use in the healthcare sector, in poultry farms as growth  
263 promoters, and the rapid dissemination of *mcr* genes via horizontal gene transfer. Even  
264 though India has banned the use of colistin in animal feeds since 2019, its implications on the  
265 spread of Pol<sup>R</sup> may be revealed a few years down the line. Interestingly, there are no reports

266 of Pol<sup>R</sup> in 16 states and 5 UTs in India, which may be due to the lack of surveillance in those  
267 States and UTs (Fig. 2B).

268 Although most of the reports used in this study indicated Pol<sup>R</sup> rates under 20%, there are a  
269 few that have reported significantly higher Pol<sup>R</sup> rates.<sup>42-47</sup> These high numbers are possibly  
270 due to the different methodologies adopted for determining polymyxin resistance. In India,  
271 various methods such as the Kirby-Bauer disk diffusion test, BMD, agar dilution, Etest,  
272 VITEK-2, gradient diffusion, colistin broth disc elution, rapid polymyxin Nordmann Poirel  
273 Test, Mikrolatest kit, BD Phoenix M50, MicroScan WalkAway 96 Plus, Micronaut-S and  
274 Modified Stokes DDT, have been used. However, as per the recommendation of the CLSI  
275 and EUCAST, BMD is the only approved method for determining polymyxin  
276 susceptibility,<sup>34,35</sup> and therefore in this study, the polymyxin resistance reports determined  
277 using the BMD method have only been included.

278 Though the primary goal of this meta-analysis was to find the overall prevalence of Pol<sup>R</sup>  
279 bacterial strains in India, our study revealed that 13.5% of the clinical isolates and 27.6% of  
280 the environmental isolates from India are resistant to polymyxins (Fig. 4). However, there  
281 were only five eligible studies that were used to analyse the environmental samples (Fig. 4C).  
282 Therefore, a larger study might be needed to confirm the observed high rate of resistance  
283 among the environmental isolates.

284 This study revealed that in 8.4% of cases, the *mcr* gene was responsible for the Pol<sup>R</sup>  
285 phenotype (Fig. 5A). In India, after the first detection of the *mcr* gene in a clinical *E. coli*  
286 isolate,<sup>48</sup> several reports of *mcr* occurrence have been published.<sup>30,32,49-51</sup> To date, six classes  
287 of *mcr* genes have been reported in India: *mcr-1*, *mcr-2*, *mcr-3*, *mcr-4*, *mcr-5*, and *mcr-9*  
288 (Table 2). Of the ten different *mcr* classes described till date, *mcr-1* was the predominant  
289 variant responsible for driving polymyxin resistance in India. In the current study, the  
290 frequency of *mcr-1* was 72% (Fig. 5C). Our analysis corroborates the recent studies that have  
291 determined the predominance of *mcr-1* gene in comparison to other *mcr* classes in the spread  
292 of colistin resistance.<sup>52-54</sup> Considering that *mcr-1* was the first plasmid-borne colistin  
293 resistance gene to be detected<sup>20</sup> it has spread across the globe in the preceding decade or so.  
294 Moreover, various retrospective surveillance for *mcr* genes have revealed their presence in  
295 samples dating back to 1980s highlighting their presence before the widespread use of  
296 colistin in the animal feeds, which has only supplemented its global spread.<sup>26,55</sup>

297 Unlike the distribution of Pol<sup>R</sup> GNB, the spread of *mcr* has been limited to nine states and  
298 two UTs in India (Fig. 5B). Among these states, Uttar Pradesh was found to be the hotspot  
299 for the spread of *mcr* variants, with 48 reports, followed by Tamil Nadu and Assam with 31  
300 and 15 *mcr* positive reports, respectively (Supplementary Table 2). However, several reports  
301 on Pol<sup>R</sup> have not provided sufficient information on *mcr* gene screening status. The limited  
302 screening for *mcr* genes among these studies may be responsible for the low rate of detection  
303 and reporting of *mcr* genes in India.

304 As mentioned previously, *mcr* genes are largely plasmid-borne, and various types of plasmids  
305 are involved in carrying *mcr* genes in GNB.<sup>26,56</sup> In India, different *mcr* variants were found to  
306 be linked with plasmids including IncHI2, InCHI2A, IncX1, IncX4, and FIA Inc.<sup>32,43,57</sup> The  
307 role of these plasmids conferring resistance to carbapenems, cephalosporins, and fosfomicin  
308 has also been established previously.<sup>58,59</sup> Although plasmids are the primary mobile genetic  
309 elements through which *mcr* genes disseminate among bacterial species, their chromosomal  
310 integration has also been reported in different bacterial species in India.<sup>60-63</sup> The major  
311 advantage of chromosomal integration of *mcr* genes could be their efficient vertical  
312 transmission in the absence of polymyxin selection. Some intrinsically resistant bacteria also  
313 harbour the *mcr* genes and can potentially spread them to the polymyxin-susceptible species  
314 in the environment.<sup>64</sup> Moreover, few studies have reported the presence of the *mcr-1*, *mcr-3*,  
315 and *mcr-9* genes in bacterial species that are susceptible to polymyxin.<sup>51,65</sup> This is primarily  
316 due to the insertional inactivation of *mcr-1* and *mcr-3* genes.<sup>51,65</sup> However, in the case of *mcr-*  
317 *9* positive *Enterobacter hormaechei* strain, *qseBC* TCS genes were absent downstream<sup>66</sup>  
318 which has been previously described to induce the colistin resistance phenotype by  
319 upregulating the *mcr-9* gene expression in response to the subinhibitory concentration of  
320 colistin.<sup>67</sup>

321 This meta-analysis has certain limitations. First, the current study included articles available  
322 in the English language only, as a result, publications in other languages have been excluded.  
323 Second, we searched reports from databases including PubMed, Google Scholar, Scopus, and  
324 Science Direct, so may have missed publications indexed in other databases. Third, as certain  
325 GNB species are intrinsically resistant to polymyxins, reports on polymyxin resistance from  
326 the environmental strains may have been biased toward such species.

327 **CONCLUSION**

328 The present study found that the rate of Pol<sup>R</sup> bacterial strains in India was 15.0%, which is  
329 higher than the global average. Pol<sup>R</sup> was determined among 13.5% and 27.6% of the bacterial  
330 isolates from the clinical and environmental sources respectively. While Pol<sup>R</sup> strains have  
331 been reported from most of the Indian States and UTs, there are still regions where adequate  
332 data are not available, warranting monitoring and surveillance. This study further found that  
333 in 8.4% of Pol<sup>R</sup> strains, the phenotype was determined by *mcr* genes carried on plasmids.  
334 This may be grossly underestimated due to the lack of *mcr* surveillance data in many  
335 published articles. As polymyxins are one of the last option antibiotics available against GNB  
336 pathogens, efforts to increase their clinical longevity is paramount. However, the increasing  
337 incidence of polymyxin resistance in clinics and the environment has the potential to limit  
338 antibiotic treatment options. Therefore, along with developing better versions of polymyxins  
339 and/or their derivatives, it is also important to devise strategies for monitoring the frequency  
340 of Pol<sup>R</sup> bacterial species and, the prevalence of *mcr* genes in them. Sustained measures need  
341 to be in place to contain further spread of the polymyxin resistance phenotype in the near  
342 future.

#### 343 **Author Contributions**

344 Conceptualization: SKD, AKP, and SSM; Data extraction and analysis: SKD, IP, AKP, and  
345 SSM; Data validation: SKD and IP; Manuscript writing and reviewing: SKD, AKP, and  
346 SSM. All authors agreed to the submitted version.

#### 347 **Funding**

348 This work is supported by the funds received from the Science and Technology Department,  
349 Govt. of Odisha (Grant no. ST-BT-MISC-0005-2023-2463/ST, dt. 23-05-2023).  
350 Infrastructure support from the “Centre of Excellence on Bioprospecting of Ethno-  
351 pharmaceuticals of Southern Odisha (CoE-BESO)” to the Dept. of Biotechnology,  
352 Berhampur University is gratefully acknowledged. Indira Padhy is a recipient of the “Biju  
353 Patnaik Research Fellowship (BPRF)” from the Science and Technology Department, Govt.  
354 of Odisha.

#### 355 **Transparency Declarations**

356 The authors declare that the research was conducted in the absence of any commercial or  
357 financial relationships that could be construed as a potential conflict of interest.

#### 358 **Legends to Figures**

359 **Figure. 1.** The PRISMA flow diagram for the selection, inclusion, and exclusion of studies.

360 **Figure. 2.** (A) Forest plots demonstrating the event rate of Pol<sup>R</sup> bacteria in India. The  
361 Comprehensive Meta-Analysis software V4 (Biostat Inc. USA) was used for the calculation  
362 of the event rate and 95% confidence interval. (B) Distribution of Pol<sup>R</sup> bacteria across  
363 different States and Union Territories (UTs) of India from 41 studies. States and UTs in India  
364 that have reported Pol<sup>R</sup> strains are shaded in green.

365 **Figure. 3.** Forest plots representing the event rate of Pol<sup>R</sup> bacteria in different states of India  
366 (A) Delhi, (B) Odisha, (C) Tamil Nadu, and (D) Uttar Pradesh.

367 **Figure. 4.** (A) Pie chart showing the prevalence of Pol<sup>R</sup> bacteria in India based on the source  
368 of their isolation. (B) Forest plots revealing the event rate of Pol<sup>R</sup> bacteria in clinical isolates  
369 in India. (C) Forest plots demonstrating the event rate of Pol<sup>R</sup> bacteria in environmental  
370 isolates in India.

371 **Figure. 5.** (A) Forest plots demonstrating the contribution of the *mcr* genes in the  
372 development of polymyxin resistance in India. (B) Spread of *mcr* genes across different  
373 States and UTs of India. States and UTs that have reported *mcr*-positive strains are shaded in  
374 orange. (C) Pie chart showing the prevalence of reported classes of *mcr* genes in India.

375 **REFERENCES**

- 376 1. Murray CJ, Ikuta KS, Sharara F, *et al.* Global burden of bacterial antimicrobial resistance in 2019:  
377 a systematic analysis. *The Lancet* 2022; S0140673621027240.
- 378 2. O'Neill J. An audience with Jim O'Neill. *Nat Rev Drug Discov* 2016; **15**: 526–526.
- 379 3. Darby EM, Trampari E, Siasat P, *et al.* Molecular mechanisms of antibiotic resistance revisited. *Nat*  
380 *Rev Microbiol* 2023; **21**: 280–95.
- 381 4. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and  
382 Resistance Mechanisms Encoded by Plasmids or Chromosomes. *Clin Microbiol Rev* 2017; **30**: 557–  
383 96.
- 384 5. Mohapatra SS, Dwibedy SK, Padhy I. Polymyxins, the last-resort antibiotics: Mode of action,  
385 resistance emergence, and potential solutions. *J Biosci* 2021; **46**: 85.
- 386 6. Benedict RG, Langlykke AF. Antibiotic activity of *Bacillus polymyxa*. *J Bacteriol* 1947; **54**: 24.
- 387 7. Koch-Weser J, Sidel VW, Federman EB, *et al.* Adverse effects of sodium colistimethate.  
388 Manifestations and specific reaction rates during 317 courses of therapy. *Ann Intern Med* 1970; **72**:  
389 857–68.
- 390 8. Nation RL, Li J. Colistin in the 21st century: *Curr Opin Infect Dis* 2009; **22**: 535–43.
- 391 9. Vaara M. Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics. *Front*  
392 *Microbiol* 2019; **10**: 1689.
- 393 10. Hamel M, Rolain J-M, Baron SA. The History of Colistin Resistance Mechanisms in Bacteria:  
394 Progress and Challenges. *Microorganisms* 2021; **9**: 442.
- 395 11. Kwa A, Kasiakou SK, Tam VH, *et al.* Polymyxin B: similarities to and differences from colistin  
396 (polymyxin E). *Expert Rev Anti Infect Ther* 2007; **5**: 811–21.
- 397 12. Nang SC, Azad MAK, Velkov T, *et al.* Rescuing the Last-Line Polymyxins: Achievements and  
398 Challenges Barker E, ed. *Pharmacol Rev* 2021; **73**: 679–728.
- 399 13. Olaitan AO, Morand S, Rolain J-M. Mechanisms of polymyxin resistance: acquired and intrinsic  
400 resistance in bacteria. *Front Microbiol* 2014; **5**: 643.
- 401 14. Yu Z, Qin W, Lin J, Fang S, Qiu J. Antibacterial Mechanisms of Polymyxin and Bacterial  
402 Resistance. *BioMed Res Int* 2015; **2015**: 1–11.
- 403 15. Antoniadou A, Kontopidou F, Poulakou G, *et al.* Colistin-resistant isolates of *Klebsiella*  
404 *pneumoniae* emerging in intensive care unit patients: first report of a multiclonal cluster. *J Antimicrob*  
405 *Chemother* 2007; **59**: 786–90.
- 406 16. Lim LM, Ly N, Anderson D, *et al.* Resurgence of Colistin: A Review of Resistance, Toxicity,  
407 Pharmacodynamics, and Dosing. *Pharmacotherapy* 2010; **30**: 1279–91.
- 408 17. Elemam A, Rahimian J, Doymaz M. *In Vitro* Evaluation of Antibiotic Synergy for Polymyxin B-  
409 Resistant Carbapenemase-Producing *Klebsiella pneumoniae*. *J Clin Microbiol* 2010; **48**: 3558–62.

- 410 18. El-Baky RMA, Masoud SM, Mohamed DS, *et al.* Prevalence and Some Possible Mechanisms of  
411 Colistin Resistance Among Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas*  
412 *aeruginosa*. *Infect Drug Resist* 2020; **13**: 323.
- 413 19. Hejnar P, Kolář M, Hájek V. Characteristics of *Acinetobacter* strains (phenotypic classification,  
414 antibiotic susceptibility and production of  $\beta$ -lactamases) isolated from Haemocultures from patients at  
415 the teaching hospital in Olomouc. *Acta Univ Palacki Olomuc Fac Med* 1999; **142**:73-71999.
- 416 20. Liu Y-Y, Wang Y, Walsh TR, *et al.* Emergence of plasmid-mediated colistin resistance  
417 mechanism MCR-1 in animals and human beings in China: a microbiological and molecular  
418 biological study. *Lancet Infect Dis* 2016; **16**: 161–8.
- 419 21. Ma Q, Huang Y, Wang J, *et al.* Multidrug-resistant *Shigella sonnei* carrying the plasmid-mediated  
420 *mcr-1* gene in China. *Int J Antimicrob Agents* 2018; **52**: 14–21.
- 421 22. Borowiak M, Fischer J, Hammerl JA, *et al.* Identification of a novel transposon-associated  
422 phosphoethanolamine transferase gene, *mcr-5*, conferring colistin resistance in d-tartrate fermenting  
423 *Salmonella enterica* subsp. *enterica* serovar Paratyphi B. *J Antimicrob Chemother* 2017; **72**: 3317–24.
- 424 23. Zeng K, Doi Y, Patil S, *et al.* Emergence of the Plasmid-Mediated *mcr-1* Gene in Colistin-  
425 Resistant *Enterobacter aerogenes* and *Enterobacter cloacae*. *Antimicrob Agents Chemother* 2016; **60**:  
426 3862–3.
- 427 24. Padhy I, Dwibedy SK, Mohapatra SS. A molecular overview of the polymyxin-LPS interaction in  
428 the context of its mode of action and resistance development. *Microbiol Res* 2024; **283**: 127679.
- 429 25. Yin W, Li H, Shen Y, *et al.* Novel Plasmid-Mediated Colistin Resistance Gene *mcr-3* in  
430 *Escherichia coli* Bush K, ed. *mBio* 2017; **8**: e00543-17.
- 431 26. Nang SC, Li J, Velkov T. The rise and spread of *mcr* plasmid-mediated polymyxin resistance. *Crit*  
432 *Rev Microbiol* 2019; **45**: 131–61.
- 433 27. Gaballa A, Wiedmann M, Carroll LM. More than *mcr*: canonical plasmid- and transposon-  
434 encoded mobilized colistin resistance genes represent a subset of phosphoethanolamine transferases.  
435 *Front Cell Infect Microbiol* 2023; **13**: 1060519.
- 436 28. Gogry FA, Siddiqui MT, Sultan I, *et al.* Current Update on Intrinsic and Acquired Colistin  
437 Resistance Mechanisms in Bacteria. *Front Med* 2021; **8**: 677720.
- 438 29. Singh S, Pathak A, Rahman M, *et al.* Genetic Characterisation of Colistin Resistant *Klebsiella*  
439 *pneumoniae* Clinical Isolates From North India. *Front Cell Infect Microbiol* 2021; **11**: 666030.
- 440 30. Talat A, Usmani A, Khan AU. Detection of *E. coli* IncX1 Plasmid-Mediated *mcr-5.1* Gene in an  
441 Indian Hospital Sewage Water Using Shotgun Metagenomic Sequencing: A First Report. *Microb*  
442 *Drug Resist* 2022; **28**: 759–64.
- 443 31. Gogry FA, Siddiqui MT, Haq. QMohdR. Emergence of *mcr-1* conferred colistin resistance among  
444 bacterial isolates from urban sewage water in India. *Environ Sci Pollut Res* 2019; **26**: 33715–7.
- 445 32. Ghafur A, Shankar C, GnanaSoundari P, *et al.* Detection of chromosomal and plasmid-mediated  
446 mechanisms of colistin resistance in *Escherichia coli* and *Klebsiella pneumoniae* from Indian food  
447 samples. *J Glob Antimicrob Resist* 2019; **16**: 48–52.



- 448 33. Hutton B, Salanti G, Caldwell DM, *et al.* The PRISMA Extension Statement for Reporting of  
449 Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist  
450 and Explanations. *Ann Intern Med* 2015; **162**: 777–84.
- 451 34. Satlin MJ, Lewis JS, Weinstein MP, *et al.* Clinical and Laboratory Standards Institute and  
452 European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B  
453 and Colistin Clinical Breakpoints. *Clin Infect Dis* 2020: ciaa121.
- 454 35. CLSI. Colistin Breakpoints for *Pseudomonas aeruginosa* and *Acinetobacter* spp. In: Wayne PA,  
455 ed. *CLSI Rationale Document MR01*. 1st ed. Clinical and Laboratory Standards Institute, 2018.
- 456 36. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.  
457 *J Clin Epidemiol* 2001; **54**: 1046–55.
- 458 37. Egger M, Smith GD, Schneider M, *et al.* Bias in meta-analysis detected by a simple, graphical  
459 test. *BMJ* 1997; **315**: 629–34.
- 460 38. Higgins JPT, Green S eds. *Cochrane Handbook for Systematic Reviews of Interventions*. The  
461 Cochrane Collaboration; 2011. Available at: [www.handbook.cochrane.org](http://www.handbook.cochrane.org).
- 462 39. Higgins JPT, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ*  
463 2003; **327**: 557.
- 464 40. Silva KED, Rossato L, Leite AF, *et al.* Overview of polymyxin resistance in Enterobacteriaceae.  
465 *Rev Soc Bras Med Trop* 2022; **55**: e0349-2021.
- 466 41. Turnidge JD, Bell JM, Jones RN. Emergence of Colistin-Resistant *Klebsiella* spp., and  
467 *Enterobacter* spp. in the Asia-Pacific (APAC) Region: A SENTRY Antimicrobial Surveillance  
468 Program Report (2006). In: Washington DC: American Society for Microbiology, 2007.
- 469 42. Bardhan T, Chakraborty M, Bhattacharjee B. Prevalence of Colistin-Resistant, Carbapenem-  
470 Hydrolyzing Proteobacteria in Hospital Water Bodies and Out-Falls of West Bengal, India. *Int J*  
471 *Environ Res Public Health* 2020; **17**: 1007.
- 472 43. Palani GS, Ghafur A, Krishnan P, *et al.* Intestinal carriage of colistin resistant Enterobacteriaceae  
473 in hospitalized patients from an Indian center. *Diagn Microbiol Infect Dis* 2020; **97**: 114998.
- 474 44. Priyanka, Meena PR, Meghwanshi KK, *et al.* Leafy greens as a potential source of multidrug-  
475 resistant diarrhoeagenic *Escherichia coli* and *Salmonella*. *Microbiol Read Engl* 2021; **167**.
- 476 45. Rohilla R, Raina D, Singh M, *et al.* Evaluation of *Sphingomonas paucimobilis* as an emerging  
477 nosocomial pathogen in a teaching hospital in Uttarakhand. *Iran J Microbiol* 2021; **13**: 617–23.
- 478 46. Shanthini T, Manohar P, Hua X, *et al.* Detection of Hypervirulent *Klebsiella pneumoniae* from  
479 Clinical Samples in Tamil Nadu. 2023: 2023.02.19.23286158.
- 480 47. Shekhar C, Joshi N, Singh A. Prevalence of Multidrug-Resistant *Escherichia coli* in Drinking-  
481 Water in and around Ayodhya (U.P.), India. *Indian J Vet Sci Biotechnol* 2023; **19**: 112–5.
- 482 48. Kumar M, Saha S, Subudhi E. More Furious Than Ever: *Escherichia coli* -Acquired Co-resistance  
483 Toward Colistin and Carbapenems. *Clin Infect Dis* 2016: ciw508.
- 484 49. Marathe NP, Pal C, Gaikwad SS, *et al.* Untreated urban waste contaminates Indian river sediments  
485 with resistance genes to last resort antibiotics. *Water Res* 2017; **124**: 388–97.

- 486 50. Mitra S, Basu S, Rath S, *et al.* Colistin resistance in Gram-negative ocular infections: prevalence,  
487 clinical outcome and antibiotic susceptibility patterns. *Int Ophthalmol* 2020; **40**: 1307–17.
- 488 51. Ragupathi NKD, Sethuvel DPM, Anandan S, *et al.* First hybrid complete genome of *Aeromonas*  
489 *veronii* reveals chromosome-mediated novel structural variant *mcr-3.30* from a human clinical  
490 sample. *Access Microbiol* 2020; **2**.
- 491 52. Dadashi M, Sameni F, Bostanshirin N, *et al.* Global prevalence and molecular epidemiology of  
492 *mcr*-mediated colistin resistance in *Escherichia coli* clinical isolates: a systematic review. *J Glob*  
493 *Antimicrob Resist* 2022; **29**: 444–61.
- 494 53. Portes AB, Rodrigues G, Leitão MP, *et al.* Global distribution of plasmid-mediated colistin  
495 resistance *mcr* gene in *Salmonella*: A systematic review. *J Appl Microbiol* 2021: jam.15282.
- 496 54. Bastidas-Caldes C, De Waard JH, Salgado MS, *et al.* Worldwide Prevalence of *mcr*-mediated  
497 Colistin-Resistance *Escherichia coli* in Isolates of Clinical Samples, Healthy Humans, and  
498 Livestock—A Systematic Review and Meta-Analysis. *Pathogens* 2022; **11**: 659.
- 499 55. Schwarz S, Johnson AP. Transferable resistance to colistin: a new but old threat: Table 1. *J*  
500 *Antimicrob Chemother* 2016; **71**: 2066–70.
- 501 56. Li Z, Cao Y, Yi L, *et al.* Emergent Polymyxin Resistance: End of an Era? *Open Forum Infect Dis*  
502 2019; **6**: ofz368.
- 503 57. Sreejith S, Manjusha P, Prathuish P, *et al.* Predicting human risk with multidrug resistant  
504 *Enterobacter hormaechei* MS2 with MCR 9 gene isolated from the feces of healthy broiler through  
505 whole genome sequence based analysis. 2023. Available at: <https://www.researchsquare.com>.
- 506 58. Carattoli A, Villa L, Feudi C, *et al.* Novel plasmid-mediated colistin resistance *mcr-4* gene in  
507 *Salmonella* and *Escherichia coli*, Italy 2013, Spain and Belgium, 2015 to 2016. *Eurosurveillance*  
508 2017; **22**.
- 509 59. Zurfluh K, Treier A, Schmitt K, *et al.* Mobile fosfomycin resistance genes in  
510 *Enterobacteriaceae*—An increasing threat. *MicrobiologyOpen* 2020; **9**.
- 511 60. Singh S, Pathak A, Kumar A, *et al.* Emergence of Chromosome-Borne Colistin Resistance Gene  
512 *mcr-1* in Clinical Isolates of *Klebsiella pneumoniae* from India. *Antimicrob Agents Chemother* 2018;  
513 **62**: e01885-17.
- 514 61. Rahman M, Ahmad S. 549. First Report for Emergence of Chromosomal Borne Colistin  
515 Resistance Gene *mcr-1* in a Clinical *Acinetobacter Baumannii* Isolates from India. *Open Forum Infect*  
516 *Dis* 2019; **6**: S261–2.
- 517 62. Pathak A, Singh S, Kumar A, *et al.* Emergence of chromosome borne colistin resistance gene,  
518 *mcr-1* in clinical isolates of *Pseudomonas aeruginosa*. *Int J Infect Dis* 2020; **101**: 22.
- 519 63. Seethalakshmi PS, Prabhakaran A, Kiran GS, *et al.* First Report on the Circulation of *mcr-9*  
520 Bearing *Enterobacteriaceae* Isolated in a Rural Environmental Water Body of India. *SSRN Electron J*  
521 2022.
- 522 64. Premnath MAC, Prabakaran K, Sivasankar S, *et al.* Occurrence of *mcr* genes and alterations in  
523 *mgrB* gene in intrinsic colistin-resistant *Enterobacteriales* isolated from chicken meat samples. *Int J*  
524 *Food Microbiol* 2023; **404**: 110323.

- 525 65. Reddy BRC, Geetha RV, Singh M, *et al.* Mcr-1 expression in progression of colistin resistance  
526 gram negative bacilli of clinical specimens derived from Intensive Care Units, wards and hospital  
527 setting of Deccan Eco Region of Southern India. *J Pharm Negat Results* 2022; **13**: 295-305.
- 528 66. Seethalakshmi PS, Ru VPN, Prabhakaran A, *et al.* Genomic investigation unveils high-risk ESBL  
529 producing Enterobacteriaceae within a rural environmental water body. *Curr Res Microb Sci* 2024; **6**:  
530 100216.
- 531 67. Kieffer N, Royer G, Decousser J-W, *et al.* *mcr-9*, an Inducible Gene Encoding an Acquired  
532 Phosphoethanolamine Transferase in *Escherichia coli*, and Its Origin. *Antimicrob Agents Chemother*  
533 2019; **63**: e00965-19.
- 534 68. Naha S, Basak P, Sands K, *et al.* Carriage and within-host diversity of *mcr-1.1*- harbouring  
535 *Escherichia coli* from pregnant mothers: inter- and intra-mother transmission dynamics of *mcr-1.1*.  
536 *Emerg Microbes Infect* 2023; **12**: 2278899.
- 537 69. Elizabeth R, Baishya S, Kalita B, *et al.* Colistin exposure enhances expression of *eptB* in colistin-  
538 resistant *Escherichia coli* co-harboring *mcr-1*. *Sci Rep* 2022; **12**: 1348.
- 539 70. Bir R, Gautam H, Arif N, *et al.* Analysis of colistin resistance in carbapenem-resistant  
540 *Enterobacterales* and XDR *Klebsiella pneumoniae*. *Ther Adv Infect Dis* 2022; **9**: 204993612210806.
- 541 71. Elizabeth R, Wangkheimayum J, Singha KM, Chanda DD, Bhattacharjee A. Subinhibitory  
542 concentration stress of colistin enhanced PhoPQ expression in *Escherichia coli* harboring *mcr-1*. *J*  
543 *Basic Microbiol* 2021; **61**: 1029–34.
- 544 72. Roy S, Das P, Das S, *et al.* Detection of the emergence of *mcr-1* –mediated colistin-resistant  
545 *Escherichia coli* and *Klebsiella pneumoniae* through a hospital-based surveillance in an oncology  
546 center in eastern India. *Infect Control Hosp Epidemiol* 2020; **41**: 378–80.
- 547 73. Subramaniam N, Muthukrishnan A. Oral mucositis and microbial colonization in oral cancer  
548 patients undergoing radiotherapy and chemotherapy: A prospective analysis in a tertiary care dental  
549 hospital. *J Investig Clin Dent* 2019; **10**.
- 550 74. Bernasconi OJ, Kuenzli E, Pires J, *et al.* Travelers Can Import Colistin-Resistant  
551 Enterobacteriaceae, Including Those Possessing the Plasmid-Mediated *mcr-1* Gene. *Antimicrob*  
552 *Agents Chemother* 2016; **60**: 5080–4.

553 **Table 1.** Statistics to test the publication bias and heterogeneity.

| Study Name<br>(Incidence of Pol <sup>R</sup><br>bacteria) | Egger's Regression Analysis |                               |                       | Heterogeneity Analysis |                     |                    | Model<br>Used |
|---|-----------------------------|-------------------------------|-----------------------|------------------------|---------------------|--------------------|---------------|
|   | Intercept                   | 95%<br>Confidence<br>Interval | P Value<br>(2 tailed) | Q value                | P-<br>Heterogeneity | I <sup>2</sup> (%) |               |
| India   | 0.37                        | -2.73 to 3.46                 | 0.81                  | 1515.89                | 0.00                | 97.36              | Random        |
| Delhi   | -6.25                       | -21.90 to 9.4                 | 0.33                  | 167.66                 | 0.00                | 97.02              | Random        |
| Odisha  | 2.05                        | -5.52 to 9.62                 | 0.49                  | 83.95                  | 0.00                | 94.04              | Random        |
| Tamil Nadu  | 2.62                        | -6.92 to 12.17                | 0.53                  | 121.59                 | 0.00                | 94.24              | Random        |
| Uttar Pradesh   | 0.72                        | -13.49 to 14.93               | 0.9                   | 102.7                  | 0.00                | 94.16              | Random        |
| India (Clinical)  | -0.15                       | -3.2 to 2.9                   | 0.92                  | 1164.99                | 0.00                | 96.99              | Random        |
| India (Environmental)                                     | -4.66                       | -28.12 to 18.8                | 0.57                  | 999.46                 | 0.00                | 97.1               | Random        |
| <i>mcr</i> gene in Pol <sup>R</sup>                       | -1.3                        | -2.69 to 0.08                 | 0.06                  | 129.71                 | 0.00                | 69.93              | Random        |

554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574


575 **Table 2.** Detailed information on the *mcr* gene reported from India.



| <i>mcr</i> gene   | Plasmid/<br>Chromosomal | Bacteria  | Source                   | References                                |
|-------------------|-------------------------|---|--------------------------|---|
| <i>mcr-9</i>      | Chromosomal             | <i>Enterobacter hormaechei</i>  | Clinical isolates        | #Seethalakshmi et al., 2024 <sup>66</sup> |
| <i>mcr-1.1</i>    | IncHI2                  | <i>E. coli</i> (10)   | Clinical isolates        | Naha et al., 2023 <sup>68</sup>           |
| <i>mcr-4</i>      | Not determined          | <i>Proteus vulgaris</i>   | Poultry meat             | Premnath et al., 2023 <sup>64</sup>       |
| <i>mcr-2</i>      | Not determined          | <i>P. vulgaris</i> , <i>Proteus mirabilis</i>   | Poultry meat             | Premnath et al., 2023 <sup>64</sup>       |
| <i>mcr-3</i>      | Not determined          | <i>Morganella morganii</i> (8),<br><i>P. vulgaris</i> (3),<br><i>P. mirabilis</i> (2),<br><i>Providencia rettgeri</i> (4) | Poultry meat             | Premnath et al., 2023 <sup>64</sup>       |
| <i>mcr-9.1</i>    | IncHI2                  | <i>E. hormaechei</i>  | Broiler faeces           | Sreejith et al., 2023 <sup>57</sup>       |
| <i>mcr-5.1</i>    | IncX1                   | <i>E. coli</i>  | Hospital sewage<br>water | Talat et al., 2022 <sup>30</sup>          |
| <i>mcr-1</i>      | FIA Inc                 | <i>E. coli</i>  | Clinical isolates        | Elizabeth et al., 2022 <sup>69</sup>      |
| <i>mcr-1</i>      | Not determined          | <i>Klebsiella pneumoniae</i>  | Clinical isolates        | Bir et al., 2022 <sup>70</sup>            |
| <i>mcr-1</i> (2)  | Plasmid                 | <i>E. coli</i> ( <i>COL<sup>S</sup></i> )*, <i>E. coli</i><br>( <i>COL<sup>R</sup></i> )                                  | Clinical isolates        | Reddy et al., 2022 <sup>65</sup>          |
| <i>mcr-1</i> (19) | Chromosomal, Plasmid    | <i>Klebsiella pneumoniae</i> (19)   | Clinical isolates        | Singh et al., 2021 <sup>29</sup>          |
| <i>mcr-1</i> (2)  | Not determined          | <i>E. coli</i> (2)  | Clinical isolates        | Elizabeth et al., 2021 <sup>71</sup>      |

|                   |                        |  |                         |   |
|-------------------|------------------------|--|-------------------------|---|
| <i>mcr-1</i> (4)  | Chromosomal            | <i>Pseudomonas aeruginosa</i>                            | Clinical isolates       | Singh et al., 2021 <sup>29</sup>                |
| <i>mcr-3.30</i>   | Chromosomal            | <i>Aeromonas veronii</i> (COL <sup>S</sup> )*            | Clinical isolates       | Ragupathi et al., 2020 <sup>51</sup>            |
| <i>mcr-1</i> (2)  | Not determined         | <i>E. coli</i>   | Clinical isolates       | Roy et al., 2020 <sup>72</sup>                  |
| <i>mcr-1</i>      | Not determined         | <i>K. pneumoniae</i>                                     | Clinical isolates       | Roy et al., 2020 <sup>72</sup>                  |
| <i>mcr-1</i> (2)  | IncX4                  | <i>E. coli</i>   | Clinical isolates       | Palani et al., 2020 <sup>43</sup>               |
| <i>mcr-1</i> (2)  | Not determined         | <i>Enterobacter cloacae</i>                              | Clinical isolates       | Mitra et al., 2020 <sup>50</sup>                |
| <i>mcr-2</i> (3)  | Not determined         | <i>Burkholderia cepacia</i>                              | Clinical isolates       | Mitra et al., 2020 <sup>50</sup>                |
| <i>mcr-2</i>      | Not determined         | <i>Pseudomonas aeruginosa</i>                            | Clinical isolates       | Mitra et al., 2020 <sup>50</sup>                |
| <i>mcr-1</i>      | Not determined         | Not mentioned  | Clinical isolates       | Pathak et al., 2020 <sup>62</sup>               |
| <i>mcr-1</i> (5)  | Plasmid                | <i>E. coli</i> , <i>A. veronii</i> , <i>A. dhakensis</i> | Sewage water            | Gogry et al., 2019 <sup>31</sup>                |
| <i>mcr-1</i>      | Not determined         | <i>E. coli</i>   | Clinical isolates       | Subramaniam & Muthukrishnan, 2019 <sup>73</sup> |
| <i>mcr-1</i> (20) | Chromosomal            | <i>Acinetobacter baumannii</i>                           | Clinical isolates       | Rahman & Ahmad., 2019 <sup>61</sup>             |
| <i>mcr-1</i> (3)  | IncX1, IncHI2, IncHI2A | <i>E. coli</i>   | Poultry and mutton meat | Ghafur et al., 2019 <sup>32</sup>               |
| <i>mcr-1</i> (4)  | Chromosomal            | <i>K. pneumoniae</i>                                     | Clinical isolates       | Singh et al., 2018 <sup>60</sup>                |
| <i>mcr-1</i>      | Not determined         | Not mentioned  | River sediment          | Marathe et al., 2017 <sup>49</sup>              |
| <i>mcr-1</i>      | Plasmid                | <i>E. coli</i>   | Clinical isolates       | Kumar et al., 2016 <sup>48</sup>                |
| <i>mcr-1</i>      | IncHI2                 | <i>E. coli</i>   | Human stool sample      | Bernasconi et al., 2016 <sup>74</sup>           |


576 Species denoted with \* mark indicate insertional inactivation of the *mcr* gene, which leads to polymyxin susceptibility. The number  
577 mentioned in the brackets represents the number of *mcr* reported. # This paper was published in 2023 as an online early version and  
578 therefore included in the study.






**A****B**


## A Delhi




## B Odisha




## C Tamil Nadu




## D Uttar Pradesh




**A**




**B**



**C**







B



C

